Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nutriband Inc - SIC # 3842 - ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AND SUPPLIES
Ticker
Exchange
SIC #
Website
Latest Ticker
NTRB
Nasdaq
3842
https://nutriband.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nutriband Inc
Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch
- Mar 27th, 2024 9:50 am
Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting
- Mar 25th, 2024 11:00 am
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting
- Mar 4th, 2024 12:00 pm
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
- Jan 29th, 2024 12:00 pm
Nutriband CEO Publishes Letter to Shareholders
- Jan 26th, 2024 12:00 pm
Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
- Jan 5th, 2024 2:15 pm
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
- Nov 28th, 2023 12:00 pm
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
- Nov 8th, 2023 12:00 pm
Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales of $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm
- Oct 11th, 2023 11:42 am
Nutriband Unveils Groundbreaking Innovation in Transdermal Medications
- Sep 20th, 2023 1:15 pm
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
- Sep 20th, 2023 11:30 am
Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023
- Sep 12th, 2023 11:00 am
Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
- Sep 11th, 2023 11:00 am
Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador
- Aug 30th, 2023 12:00 pm
Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings
- Jul 27th, 2023 12:30 pm
Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission
- Jul 14th, 2023 1:20 pm
Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology
- Jun 23rd, 2023 11:00 am
Nutriband to Attend 2023 BIO International Convention
- May 10th, 2023 12:00 pm
Nutriband Full Year 2023 Earnings: Misses Expectations
- Apr 29th, 2023 12:13 pm
Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023
- Apr 27th, 2023 12:00 pm
Scroll